by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discusses the role of Lp(a) in cardiovascular risk and the emerging therapies designed to target and lower Lp(a) levels. Read...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy. Read More
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles IVIG treatment significantly boosts platelet counts in pregnant people with thrombocytopenia, revealing key predictors for effective response and optimizing clinical decisions. Read More